Construction of a predictive model for gastric cancer neuroaggression and clinical validation analysis: A single-center retrospective study

Table 2 Energy spectrum computed tomography parameter analysis of 80 gastric cancer patients

Project	PNI positive group (n = 54)	PNI negative (n = 26)	T/Z value	P value
Arterial phase
CT value [Hu, M (Q1, Q3)]	67.240 (56.800, 80.290)	59.130 (52.585, 71.875)	1.141	0.264
CT60 kev [Hu, M (Q1, Q3)]	88.040 (72.260, 107.690)	62.370 (60.235, 75.330)	3.018	0.002
CT70 kev [Hu, M (Q1, Q3)]	68.690 (59.260, 86.120)	56.750 (50.760, 67.735)	2.584	0.009
CT80 kev (Hu, mean ± SD)	61.944 ± 14.476	50.405 ± 9.996	2.584	0.014
CT90 kev (Hu, mean ± SD)	54.610 ± 11.875	45.160 ± 8.884	2.540	0.015
CT100 kev (Hu, mean ± SD)	49.912 ± 10.568	41.404 ± 8.025	2.562	0.014
CT110 kev (Hu, mean ± SD)	46.061 ± 9.261	38.783 ± 7.537	2.463	0.018
IC [μg/cm³, M (Q1, Q3)]	14.400 (11.320, 18.720)	11.310 (10.375, 13.815)	1.863	0.064
ICao (μg/cm³, mean ± SD)	105.161 ± 21.732	114.863 ± 18.730	-1.380	0.176
NIC [M (Q1, Q3)]	0.135 (0.097, 0.205)	0.097 (0.090, 0.125)	1.891	0.060
Portal venous phase
CT value (Hu, mean ± SD)	97.302 ± 21.606	78.460 ± 15.938	2.792	0.008
CT60 kev[Hu, M (Q1, Q3)]	120.317 ± 28.755	97.011 ± 23.240	2.544	0.015
CT70 kev[Hu, M (Q1, Q3)]	94.877 ± 21.566	80.289 ± 19.614	2.061	0.046
CT80 kev (Hu, mean ± SD)	78.673 ± 17.013	65.790 ± 14.930	2.329	0.125
CT90 kev (Hu, mean ± SD)	67.918 ± 14.126	57.403 ± 12.745	2.273	0.029
CT100 kev (Hu, mean ± SD)	60.452 ± 12.191	51.541 ± 11.360	2.212	0.033
CT110 kev (Hu, mean ± SD)	55.154 ± 10.891	47.410 ± 10.376	2.138	0.039
IC [μg/cm³, M (Q1, Q3)]	55.154 ± 10.891	18.270 (13.440, 18.960)	2.902	0.003
ICao [ug/cm³, M (Q1, Q3)]	48.350 (40.200, 52.150)	44.180 (36.690, 51.945)	0.462	0.648
NIC (mean ± SD)	0.528 ± 0.184	0.402 ± 0.098	2.799	0.008

CT: Computed tomography; IC: Iodine concentration; ICao: Normalized iodine concentration in the same abdominal aorta; NIC: Normalized iodine concentration; M: Median.